Biomerica Inc (BMRA)
NASDAQ:BMRA
Want to see BMRA full AI Analyst Report?
BMRA Stock Chart & Stats
$2.88
-$0.02(-5.81%)
At close: 4:00 PM EST
$2.88
-$0.02(-5.81%)
Day’s Range― - ―
52-Week Range$1.87 - $4.60
Previous CloseN/A
Volume74.49K
Average Volume (3M)190.48K
Market Cap
$7.26M
Enterprise Value$6.12M
Total Cash (Recent Filing)$1.34M
Total Debt (Recent Filing)$193.00K
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding3,090,269
10 Day Avg. Volume453,881
30 Day Avg. Volume190,481
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.71
Price to Sales (P/S)1.32
P/FCF Ratio-1.81
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit32.72
Enterprise Value/Ebitda-1.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low absolute debt and a debt-to-equity around 0.06 materially reduce refinancing and solvency risk. That durable balance-sheet characteristic preserves optionality and gives management time to execute operational fixes or raise capital under less distress.
Diversified DistributionA hybrid go-to-market model (direct sales plus third-party distributors and international partners) spreads commercial risk and supports global reach. This structural distribution mix better positions the company to scale adoption across clinical labs and hospitals over time.
Narrowing LossesReported operating losses have contracted versus the worst prior period, indicating improving expense control or operational efficiency. Sustained narrowing is a durable precursor to breakeven if matched by stabilized or recovering revenue and improved unit economics.
Bears Say
Weak Revenue & MarginsTTM revenue has declined sharply to roughly $4.3M while gross margin is only about 4%, signaling poor product economics and limited pricing power. Such low margins structurally constrain the ability to cover fixed costs and achieve sustainable profitability without product or mix changes.
Persistent Cash BurnOperating and free cash flows have been negative across reported periods, with a TTM burn near $3.2M. Persistent cash outflows force reliance on external funding, increasing dilution or debt risk and reducing runway for strategic investments or commercialization efforts.
Eroding Equity & ReturnsShareholders' equity has fallen materially and ROE is deeply negative, reflecting capital erosion from sustained losses. A weakened equity base raises dilution and funding risk and reduces the firm’s resilience and capacity to pursue growth or invest in higher-margin product development.
Biomerica News
BMRA FAQ
What was Biomerica Inc’s price range in the past 12 months?
Biomerica Inc lowest stock price was $1.87 and its highest was $4.60 in the past 12 months.
What is Biomerica Inc’s market cap?
Biomerica Inc’s market cap is $7.26M.
When is Biomerica Inc’s upcoming earnings report date?
Biomerica Inc’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were Biomerica Inc’s earnings last quarter?
Biomerica Inc released its earnings results on Apr 13, 2026. The company reported -$0.436 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.436.
Is Biomerica Inc overvalued?
According to Wall Street analysts Biomerica Inc’s price is currently Overvalued.
Does Biomerica Inc pay dividends?
Biomerica Inc does not currently pay dividends.
What is Biomerica Inc’s EPS estimate?
Biomerica Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomerica Inc have?
Biomerica Inc has 3,090,269 shares outstanding.
What happened to Biomerica Inc’s price movement after its last earnings report?
Biomerica Inc reported an EPS of -$0.436 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.962%.
Which hedge fund is a major shareholder of Biomerica Inc?
Currently, no hedge funds are holding shares in BMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biomerica Inc
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Technical Analysis
Strata Skin Sciences
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
―
Ownership Overview
13.18% Insiders
6.66% Mutual Funds
0.03% Other Institutional Investors
79.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---